Esoterix
Esoterix is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
B7841007 - An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months
Sponsor Swedish Orphan Biovitrum AB (publ)
- Start (EU)
- Latest update
- Estimated end
A multinational, prospective, open-label, roll-over study (LIBERTY) to provide post-trial access to treatment for patients with haemophilia A who have completed a previous trial with efanesoctocog alfa
Sponsor Swedish Orphan Biovitrum AB (publ)
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2b, multicenter, randomized, double-blind study of safety and efficacy of TAK-755 (rADAMTS13) with minimal to no plasma exchange (PEX) in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Esoterix?
The 2026-10-09 snapshot links Esoterix to 4 distinct CTIS trials. Recorded services include Laboratory services, VWF antigen, VWF Rco:activity. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Esoterix?
The most frequently recorded therapeutic areas are Blood Disorders. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Esoterix conducted?
The linked trials record locations in 18 countries, including Spain, Italy, Austria, Germany, France. These are trial locations, not confirmed office locations or countries where Esoterix delivered services.
What can this page tell me about Esoterix's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Esoterix. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Esoterix Inc.